Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Advanced Cancer × Magnetic Resonance Spectroscopy × Clear all

Sponsor

Conditions

Breast Neoplasms 23 Prostatic Neoplasms 21 Carcinoma, Non-Small-Cell Lung 13 Glioma 12 Neoplasm Metastasis 11 Lymphoma 10 Glioblastoma 10 Neuroblastoma 9 Lung Neoplasms 8 Carcinoma, Renal Cell 8 Brain Neoplasms 8 Medulloblastoma 7 Ovarian Neoplasms 6 Neoplasms 6 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Fallopian Tube Neoplasms 6 Carcinoma, Hepatocellular 6 Uterine Cervical Neoplasms 5 Sarcoma 5 Rectal Neoplasms 5 Osteosarcoma 5 Neuroendocrine Tumors 5 Melanoma 5 Ependymoma 5 Central Nervous System Neoplasms 5 Wilms Tumor 4 Triple Negative Breast Neoplasms 4 Rhabdomyosarcoma 4 Rhabdoid Tumor 4

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡